Study: Macrolide antibiotics may benefit non-CF bronchiectasis patients

Azithromycin and erythromycin significantly decreased the number of pulmonary exacerbations in patients with non-cystic fibrosis bronchiectasis, but long-term use increased resistance to the drugs, according to two studies in the Journal of the American Medical Association. Azithromycin and erythromycin enhanced lung function, while azithromycin significantly improved quality of life.

View Full Article in:

PhysiciansBriefing.com · MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA